Ratings by Goldman Sachs (Chris Shibutani)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/11/2024 | Eli Lilly | LLY | Maintain | Neutral (N/A) |
|
Details | ||
| 4/1/2024 | Erasca Inc | ERAS | Maintain | Buy (N/A) |
|
Details | ||
| 3/21/2024 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/1/2024 | Revance Therapeutic | RVNC | Maintain | Neutral (N/A) |
|
Details | ||
| 2/29/2024 | Schrodinger | SDGR | Maintain | Neutral (N/A) |
|
Details | ||
| 2/28/2024 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 2/28/2024 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Neutral (N/A) |
|
Details | ||
| 2/20/2024 | Royalty Pharma | RPRX | Maintain | Buy (N/A) |
|
Details | ||
| 2/20/2024 | Organon & Co. | OGN | Maintain | Neutral (N/A) |
|
Details | ||
| 2/12/2024 | United Therapeutics Corp. | UTHR | Upgrade | Neutral (Sell) |
211.74 (234.06) |
10.54% | Details | |
| 2/5/2024 | Abbvie | ABBV | Maintain | Buy (N/A) |
|
Details | ||
| 2/2/2024 | Merck | MRK | Maintain | Conviction Buy (N/A) |
|
Details | ||
| 1/30/2024 | Alkermes | ALKS | Maintain | Buy (N/A) |
|
Details | ||
| 1/25/2024 | Neurocrine Bio. | NBIX | Maintain | Buy (N/A) |
|
Details | ||
| 1/9/2024 | Revance Therapeutic | RVNC | Downgrade | Neutral (Buy) |
7.05 (3.64) |
-48.37% | Details | |
| 12/15/2023 | Pfizer | PFE | Maintain | Buy (N/A) |
|
Details | ||
| 12/12/2023 | Pfizer | PFE | Maintain | Buy (N/A) |
|
Details | ||
| 12/12/2023 | Eli Lilly | LLY | Maintain | Neutral (N/A) |
|
Details | ||
| 12/12/2023 | Bristol-Myers Squibb Co. | BMY | Maintain | Buy (N/A) |
|
Details | ||
| 12/11/2023 | Abbvie | ABBV | Upgrade | Buy (Neutral) |
149.28 (167.89) |
12.47% | Details | |
| 11/3/2023 | Organon & Co. | OGN | Downgrade | Neutral (Buy) |
13.11 (18.00) |
37.3% | Details | |
| 11/3/2023 | Seres Therapeutics | MCRB | Maintain | Sell (N/A) |
|
Details | ||
| 11/1/2023 | Pfizer | PFE | Maintain | Buy (N/A) |
|
Details | ||
| 10/30/2023 | Bristol-Myers Squibb Co. | BMY | Maintain | Buy (N/A) |
|
Details | ||
| 10/27/2023 | Bristol-Myers Squibb Co. | BMY | Maintain | Buy (N/A) |
|
Details | ||
| 10/16/2023 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Neutral (N/A) |
|
Details | ||
| 10/13/2023 | Arcutis Biotherapeutics Inc. | ARQT | Downgrade | Neutral (Buy) |
4.51 (8.94) |
98.23% | Details | |
| 10/11/2023 | Syndax Pharmaceuticals | SNDX | New Coverage | Buy (N/A) |
12.50 (20.96) |
67.68% | Details | |
| 9/21/2023 | Revance Therapeutic | RVNC | Maintain | Buy (N/A) |
|
Details | ||
| 8/9/2023 | Eli Lilly | LLY | Maintain | Neutral (N/A) |
|
Details | ||
| 8/8/2023 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 8/7/2023 | Schrodinger | SDGR | Maintain | Neutral (N/A) |
|
Details | ||
| 7/31/2023 | Revance Therapeutic | RVNC | Maintain | Buy (N/A) |
|
Details | ||
| 6/6/2023 | Erasca Inc | ERAS | Maintain | Buy (N/A) |
|
Details | ||
| 5/16/2023 | Erasca Inc | ERAS | Maintain | Buy (N/A) |
|
Details | ||
| 5/10/2023 | EQRx, Inc. | EQRX | Maintain | Neutral (N/A) |
|
Details | ||
| 5/10/2023 | Repare Therapeutics | RPTX | Maintain | Buy (N/A) |
|
Details | ||
| 5/1/2023 | Revance Therapeutic | RVNC | Maintain | Buy (N/A) |
|
Details | ||
| 3/28/2023 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/21/2023 | Amylyx Pharmaceuticals inc. | AMLX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/14/2023 | Amylyx Pharmaceuticals inc. | AMLX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/3/2023 | Inova Technology, Inc. | INVA | Maintain | Neutral (N/A) |
|
Details | ||
| 3/1/2023 | Revolution | RVMD | Maintain | Neutral (N/A) |
|
Details | ||
| 2/27/2023 | Nektar Therapeutics | NKTR | Maintain | Sell (N/A) |
|
Details | ||
| 2/24/2023 | Erasca Inc | ERAS | New Coverage | Buy (N/A) |
3.65 (1.85) |
-49.32% | Details | |
| 2/17/2023 | Alkermes | ALKS | Maintain | Buy (N/A) |
|
Details | ||
| 1/31/2023 | Prometheus Biosciences Inc | RXDX | Maintain | Buy (N/A) |
|
Details | ||
| 1/31/2023 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 12/19/2022 | Schrodinger | SDGR | New Coverage | Buy (N/A) |
19.89 (24.49) |
23.13% | Details | |
| 12/19/2022 | Ventyx Biosciences Inc | VTYX | New Coverage | Buy (N/A) |
33.45 (4.30) |
-87.14% | Details | |
| 12/13/2022 | Abbvie | ABBV | Maintain | Neutral (N/A) |
|
Details | ||
| 12/13/2022 | Pfizer | PFE | Upgrade | Buy (Neutral) |
52.16 (26.26) |
-49.65% | Details | |
| 12/7/2022 | Prometheus Biosciences Inc | RXDX | Maintain | Buy (N/A) |
|
Details | ||
| 12/5/2022 | United Therapeutics Corp. | UTHR | New Coverage | Sell (N/A) |
275.61 (211.74) |
-23.17% | Details | |
| 11/17/2022 | Exscientia PLC | EXAI | Maintain | Buy (Buy) |
|
Details | ||
| 11/11/2022 | EQRx, Inc. | EQRX | Downgrade | Neutral (Buy) |
3.89 (2.34) |
-39.85% | Details | |
| 11/9/2022 | Royalty Pharma | RPRX | Maintain | Buy (N/A) |
|
Details | ||
| 11/8/2022 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 11/8/2022 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 11/8/2022 | Entrada Therapeutics | TRDA | Maintain | Neutral (N/A) |
|
Details | ||
| 11/7/2022 | Eli Lilly | LLY | Maintain | Neutral (N/A) |
|
Details | ||
| 9/27/2022 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Buy (N/A) |
|
Details | ||
| 9/22/2022 | Revance Therapeutic | RVNC | New Coverage | Buy (N/A) |
25.80 (3.64) |
-85.89% | Details | |
| 9/8/2022 | Amylyx Pharmaceuticals inc. | AMLX | Maintain | Neutral (N/A) |
|
Details | ||
| 8/15/2022 | Entrada Therapeutics | TRDA | Maintain | Neutral (N/A) |
|
Details | ||
| 8/12/2022 | Prometheus Biosciences Inc | RXDX | Maintain | Buy (N/A) |
|
Details | ||
| 8/9/2022 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 8/3/2022 | Kymera Therapeutics | KYMR | New Coverage | Buy (N/A) |
21.48 (34.35) |
59.92% | Details | |
| 7/20/2022 | Inova Technology, Inc. | INVA | New Coverage | Neutral (N/A) |
14.51 (14.93) |
2.89% | Details | |
| 7/20/2022 | Prometheus Biosciences Inc | RXDX | New Coverage | Buy (N/A) |
29.29 (199.92) |
582.55% | Details | |
| 7/6/2022 | Amylyx Pharmaceuticals inc. | AMLX | Maintain | Neutral (N/A) |
|
Details | ||
| 6/13/2022 | EQRx, Inc. | EQRX | New Coverage | Buy (N/A) |
4.10 (3.89) |
-5.12% | Details | |
| 6/6/2022 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Buy (N/A) |
|
Details | ||
| 5/13/2022 | Entrada Therapeutics | TRDA | Maintain | Neutral (N/A) |
|
Details | ||
| 4/27/2022 | Organon & Co. | OGN | New Coverage | Buy (N/A) |
31.66 (18.00) |
-43.15% | Details | |
| 4/27/2022 | Royalty Pharma | RPRX | New Coverage | Buy (N/A) |
41.83 (27.82) |
-33.49% | Details | |
| 4/20/2022 | Johnson & Johnson | JNJ | Maintain | Neutral (N/A) |
|
Details | ||
| 4/20/2022 | Alkermes | ALKS | New Coverage | Buy (N/A) |
28.48 (24.07) |
-15.48% | Details | |
| 4/18/2022 | Nektar Therapeutics | NKTR | Downgrade | Sell (Neutral) |
6.16 (1.36) |
-77.92% | Details | |
| 4/1/2022 | Amylyx Pharmaceuticals inc. | AMLX | Downgrade | Neutral (Buy) |
14.93 (1.98) |
-86.74% | Details | |
| 3/31/2022 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/29/2022 | Tango Therapeutics Inc. | TNGX | Maintain | Buy (N/A) |
|
Details | ||
| 3/17/2022 | Arcutis Biotherapeutics Inc. | ARQT | New Coverage | Buy (N/A) |
15.98 (8.94) |
-44.06% | Details | |
| 3/17/2022 | Repare Therapeutics | RPTX | New Coverage | Buy (N/A) |
12.12 (3.26) |
-73.1% | Details | |
| 3/1/2022 | Revolution | RVMD | Maintain | Neutral (N/A) |
|
Details | ||
| 2/25/2022 | Neurocrine Bio. | NBIX | Upgrade | Buy (Neutral) |
85.55 (133.66) |
56.24% | Details | |
| 2/7/2022 | Bristol-Myers Squibb Co. | BMY | Maintain | Buy (N/A) |
|
Details | ||
| 2/3/2022 | Abbvie | ABBV | Maintain | Neutral (N/A) |
|
Details | ||
| 2/1/2022 | Amylyx Pharmaceuticals inc. | AMLX | New Coverage | Buy (N/A) |
20.00 (14.93) |
-25.35% | Details | |
| 1/26/2022 | Johnson & Johnson | JNJ | Maintain | Neutral (N/A) |
|
Details | ||
| 12/17/2021 | Abbvie | ABBV | New Coverage | Neutral (N/A) |
131.78 (167.89) |
27.4% | Details | |
| 12/17/2021 | Pfizer | PFE | New Coverage | Neutral (N/A) |
61.25 (26.26) |
-57.13% | Details | |
| 12/17/2021 | Eli Lilly | LLY | New Coverage | Neutral (N/A) |
279.04 (731.33) |
162.09% | Details | |
| 12/17/2021 | Johnson & Johnson | JNJ | New Coverage | Neutral (N/A) |
173.01 (149.12) |
-13.81% | Details | |
| 12/17/2021 | Bristol-Myers Squibb Co. | BMY | New Coverage | Buy (N/A) |
62.17 (49.14) |
-20.96% | Details | |
| 12/17/2021 | Merck | MRK | New Coverage | Conviction Buy (N/A) |
75.91 (126.94) |
67.22% | Details | |
| 11/23/2021 | Entrada Therapeutics Inc. | TRDA | New Coverage | Neutral (N/A) |
32.79 (13.10) |
-60.05% | Details | |
| 11/11/2021 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 11/2/2021 | Neurocrine Bio. | NBIX | Maintain | Neutral (N/A) |
|
Details | ||
| 10/26/2021 | Exscientia PLC | EXAI | New Coverage | Buy (N/A) |
22.20 (4.25) |
-80.86% | Details | |
| 9/7/2021 | Tango Therapeutics Inc. | TNGX | New Coverage | Buy (N/A) |
12.00 (7.31) |
-39.08% | Details | |
| 8/12/2021 | Revolution | RVMD | Downgrade | Neutral (Buy) |
26.90 (36.43) |
35.43% | Details | |
| 8/11/2021 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 7/23/2021 | Seres Therapeutics | MCRB | Downgrade | Sell (Neutral) |
20.83 (0.62) |
-97.02% | Details | |
| 5/18/2021 | Exelixis | EXEL | New Coverage | Sell (N/A) |
25.24 (22.87) |
-9.39% | Details | |
| 5/18/2021 | Seres Therapeutics | MCRB | New Coverage | Neutral (N/A) |
21.80 (0.62) |
-97.16% | Details | |
| 5/18/2021 | Neurocrine Bio. | NBIX | New Coverage | Neutral (N/A) |
93.08 (85.55) |
-8.09% | Details | |
| 5/18/2021 | Nektar Therapeutics | NKTR | New Coverage | Neutral (N/A) |
18.19 (1.36) |
-92.52% | Details | |
| 5/18/2021 | BioNTech | BNTX | New Coverage | Neutral (N/A) |
198.30 (88.01) |
-55.62% | Details | |
| 5/18/2021 | Revolution | RVMD | New Coverage | Buy (N/A) |
31.48 (36.43) |
15.72% | Details | |
| 5/18/2021 | Arena Pharma | ARNA | New Coverage | Buy (N/A) |
60.89 (99.98) |
64.2% | Details |
